Document Detail

Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11).
Jump to Full Text
MedLine Citation:
PMID:  24781315     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Antiretroviral therapy (ART) has major benefits during pregnancy, both for maternal health and to prevent mother-to-child transmission of HIV. Safety issues, including teratogenic risk, need to be evaluated. We estimated the prevalence of birth defects in children born to HIV-infected women receiving ART during pregnancy, and assessed the independent association of birth defects with each antiretroviral (ARV) drug used.
METHODS AND FINDINGS: The French Perinatal Cohort prospectively enrolls HIV-infected women delivering in 90 centers throughout France. Children are followed by pediatricians until 2 y of age according to national guidelines. We included 13,124 live births between 1994 and 2010, among which, 42% (n = 5,388) were exposed to ART in the first trimester of pregnancy. Birth defects were studied using both European Surveillance of Congenital Anomalies (EUROCAT) and Metropolitan Atlanta Congenital Defects Program (MACDP) classifications; associations with ART were evaluated using univariate and multivariate logistic regressions. Correction for multiple comparisons was not performed because the analyses were based on hypotheses emanating from previous findings in the literature and the robustness of the findings of the current study. The prevalence of birth defects was 4.4% (95% CI 4.0%-4.7%), according to the EUROCAT classification. In multivariate analysis adjusting for other ARV drugs, maternal age, geographical origin, intravenous drug use, and type of maternity center, a significant association was found between exposure to zidovudine in the first trimester and congenital heart defects: 2.3% (74/3,267), adjusted odds ratio (AOR) = 2.2 (95% CI 1.3-3.7), p = 0.003, absolute risk difference attributed to zidovudine +1.2% (95% CI +0.5; +1.9%). Didanosine and indinavir were associated with head and neck defects, respectively: 0.5%, AOR = 3.4 (95% CI 1.1-10.4), p = 0.04; 0.9%, AOR = 3.8 (95% CI 1.1-13.8), p = 0.04. We found a significant association between efavirenz and neurological defects (n = 4) using the MACDP classification: AOR = 3.0 (95% CI 1.1-8.5), p = 0.04, absolute risk +0.7% (95% CI +0.07%; +1.3%). But the association was not significant using the less inclusive EUROCAT classification: AOR = 2.1 (95% CI 0.7-5.9), p = 0.16. No association was found between birth defects and lopinavir or ritonavir with a power >85% for an odds ratio of 1.5, nor for nevirapine, tenofovir, stavudine, or abacavir with a power >70%. Limitations of the present study were the absence of data on termination of pregnancy, stillbirths, tobacco and alcohol intake, and concomitant medication.
CONCLUSIONS: We found a specific association between in utero exposure to zidovudine and heart defects; the mechanisms need to be elucidated. The association between efavirenz and neurological defects must be interpreted with caution. For the other drugs not associated with birth defects, the results were reassuring. Finally, whatever the impact that some ARV drugs may have on birth defects, it is surpassed by the major role of ART in the successful prevention of mother-to-child transmission of HIV. Please see later in the article for the Editors' Summary.
Authors:
Jeanne Sibiude; Laurent Mandelbrot; Stéphane Blanche; Jérôme Le Chenadec; Naima Boullag-Bonnet; Albert Faye; Catherine Dollfus; Roland Tubiana; Damien Bonnet; Nathalie Lelong; Babak Khoshnood; Josiane Warszawski
Related Documents :
19246625 - Smokers' responses toward cigarette pack warning labels in predicting quit intention, s...
2323835 - Sister chromatid exchanges in peripheral lymphocytes of workers exposed to benzene, tri...
24130075 - Long-acting reversible contraception: a review in special populations.
24781315 - Association between prenatal exposure to antiretroviral therapy and birth defects: an a...
19838765 - Differences between men and women in the course of opiate dependence: is there a telesc...
16114195 - Voices from the margins part 1: narrative accounts of indigenous family violence.
Publication Detail:
Type:  Journal Article     Date:  2014-04-29
Journal Detail:
Title:  PLoS medicine     Volume:  11     ISSN:  1549-1676     ISO Abbreviation:  PLoS Med.     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-04-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101231360     Medline TA:  PLoS Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e1001635     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS Med
Journal ID (iso-abbrev): PLoS Med
Journal ID (publisher-id): PLoS
Journal ID (pmc): plosmed
ISSN: 1549-1277
ISSN: 1549-1676
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2014 Sibiude et al
License:
Received Day: 20 Month: 10 Year: 2013
Accepted Day: 19 Month: 3 Year: 2014
collection publication date: Month: 4 Year: 2014
Electronic publication date: Day: 29 Month: 4 Year: 2014
Volume: 11 Issue: 4
E-location ID: e1001635
PubMed Id: 24781315
ID: 4004551
Publisher Id: PMEDICINE-D-13-03356
DOI: 10.1371/journal.pmed.1001635

Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11) Alternate Title:Antiretroviral Therapy and Birth Defects
Jeanne Sibiude12*
Laurent Mandelbrot123
Stéphane Blanche45
Jérôme Le Chenadec26
Naima Boullag-Bonnet2
Albert Faye37
Catherine Dollfus8
Roland Tubiana910
Damien Bonnet11
Nathalie Lelong12
Babak Khoshnood12
Josiane Warszawski2613
Clara Menéndezedit1 Role: Academic Editor
1Hôpital Louis Mourier, Assistance Publique–Hôpitaux de Paris, Colombes, France
2Centre de Recherche en Épidémiologie et Santé des Populations, INSERM U1018, Le Kremlin-Bicêtre, France
3Université Paris Diderot—Paris 7, Paris, France
4Hôpital Necker, Assistance Publique–Hôpitaux de Paris, Paris, France
5EA 3620, Université Paris Descartes 5, Paris, France
6Institut National d'Etudes Démographiques, Paris, France
7Hôpital Robert Debré, Assistance Publique–Hôpitaux de Paris, Paris, France
8Hôpital Trousseau, Assistance Publique–Hôpitaux de Paris, Paris, France
9Hôpital Pitié Salpétrière, Assistance Publique–Hôpitaux de Paris, Paris, France
10INSERM U943, Paris, France
11Pediatric Cardiology, M3C Necker-Enfants Malades, Assistance Publique–Hôpitaux de Paris, Université Paris Descartes, Paris, France
12INSERM UMR S953, Université Paris 6, Paris, France
13Université Paris Sud, Le Kremlin-Bicêtre, France
Hospital Clinic Barcelona, Spain
Correspondence: * E-mail: jeannesibiude@yahoo.fr
[conflict] The authors have declared that no competing interests exist.
Contributed by footnote: Analyzed the data: JS JW. Wrote the first draft of the manuscript: JS JW. Contributed to the writing of the manuscript: JS LM JW SB DB BK. ICMJE criteria for authorship read and met: JS LM JW SB JL NB DB NL BK RT AF CD. Agree with manuscript results and conclusions: JS LM JW SB JL NB DB NL BK RT AF CD. Enrolled patients: JS LM SB RT AF CD. Conceived the study design: JS JW SB LM.

Introduction

In France and other industrialized countries, the use of antiretroviral therapy (ART) during pregnancy has led to a spectacular decrease of the mother-to-child transmission rate of HIV-1, from about 20% down to about 1% currently [1][3]. Since 2004, standard care is to treat every HIV-infected pregnant woman with triple-combination ART [4]. Many HIV-infected women are already taking these drugs for their own health when conception occurs, or start during the first trimester. Concern has been raised about the potential toxicity of these drugs during fetal development [5][8].

The risk of birth defects associated with ART has been investigated following an animal study suggesting a teratogenic effect in monkeys exposed in utero to efavirenz [9]. Results from clinical studies were discrepant. A large meta-analysis found no increased risk of birth defects [10], despite the inclusion of two recent prospective studies that found an increased risk with first-trimester exposure to efavirenz [11],[12]. The largest database for birth defects and ART today is the Antiretroviral Pregnancy Registry (APR), with 15,451 births included [13]. To date, the only antiretrovirals (ARVs) for which use during the first trimester is associated with increased rates of overall birth defects in the APR compared with the general population (2.8%) are nelfinavir (3.9%) and didanosine (4.6%); no association with specific birth defects was identified for these two drugs. Two other studies found an association between congenital heart defects (CHDs) and ART: zidovudine in one of these studies (adjusted odds ratio [AOR] = 2.04 [95% CI 1.03–4.05] for zidovudine in the first trimester compared to no zidovudine in the first trimester) [11], and any kind of ART in the other (rate of CHDs = 2.5% for children exposed in the first trimester versus 0.8% for infants exposed only later in pregnancy, p = 0.02) [14].

The diversity of the results may be due to differences between populations and the variety of follow-up protocols that determine how birth defects are diagnosed (Table 1). Moreover, definitions of birth defects differed between studies. The Metropolitan Atlanta Congenital Defects Program (MACDP) classification was most often used, and almost always adapted as described for the APR [13]. A recent Italian study found no association between ART and birth defects using the APR-modified MACDP classification [15]. Only one study used the European Surveillance of Congenital Anomalies (EUROCAT) classification, which is less inclusive than the MACDP classification [16], and several studies provided no information about the system of classification used [17][19]. Many studies suffered from lack of power. Some cases were enrolled in more than one study, leading to lower precision of risk estimates than if they were provided by totally independent studies [7],[8].

Our objective was to estimate the prevalence of birth defects in children exposed in utero to ARV drugs taken by their mothers during pregnancy in the large national prospective French Perinatal Cohort (EPF) (Agence Nationale de Recherche sur le Sida et les Hepatites [ANRS] CO1/CO11), and to assess the association of specific birth defects with each in utero ARV drug, taking several known risk factors into account.


Methods

The study was approved by the Hôpital Cochin Institutional Review Board and the French computer database watchdog commission (Comission Nationale de l'Informatique et des Libertés).

The French Perinatal Cohort (ANRS CO1/CO11)

Since 1986, EPF has prospectively enrolled pregnant HIV-infected women delivering in 90 centers throughout France [1]. In each participating maternity center, around 95% of all HIV-infected pregnant women were included, with informed consent. No specific recommendation for HIV treatment and obstetric care was made for women included in the cohort, but clinicians were encouraged to follow current French national guidelines, which include trimestrial prenatal ultrasound for all women, whatever their HIV status, and pediatric clinical and biological examinations at birth and 1, 3, 6, 12, and 18–24 mo for children exposed to maternal HIV [4],[20]. No additional ultrasound imaging was done systematically because of the study or because of the HIV status of the mother. Standardized questionnaires were filled out by clinicians, after delivery for pregnancy, and at each visit for children. Variables collected are described below. EPF coverage is estimated to be around 70% of the HIV-infected women in metropolitan France.

Study Population

Among 14,074 fetuses of 13,761 pregnancies included in EPF from 1 January 1994 to 31 December 2010, the main analysis concerned all live births exposed to ART during pregnancy (n = 13,124) (Figure 1). The small group of women not receiving ART was excluded because it could not be a valid reference group: failing to take ART was related to being socially marginalized, with inadequate access to care and follow-up, as previously reported [21]. We also excluded 43 terminations of pregnancy (TOPs) for fetal abnormalities and 90 stillbirths because, until recently, patients were enrolled after 28 wk of gestation, such that most TOPs and many stillbirths were not represented in EPF. TOPs and stillbirths were added subsequently in sensitivity analyses. No study participants, except 288 women in a collaborative ancillary analysis [14], had been previously included in any published study on birth defects.

Variables

All clinical events in infants were recorded at each visit (at birth, and at 1, 3, 6, 12, and 18–24 mo). We first coded the birth defects with International Classification of Diseases (ICD-10) codes. We then used EUROCAT inclusion criteria and guidelines in order to assess the overall prevalence of anomalies and to classify them in different organ systems [22],[23]. To facilitate comparison with other studies, we also coded birth defects according to the modified MACDP classification used by the APR [13],[24],[25], which considered as cases children presenting one major defect and/or two conditional defects. In both classifications, each child is counted only once per organ system, even if several defects included in the same organ system are described. The use of both classifications was decided a priori; the EUROCAT classification was used for the primary analysis, and the modified MACDP classification for the secondary analysis.

Maternal variables included age, geographical origin, intravenous drug use (IDU), gravidity, parity, CD4 cell count, and HIV-1 viral load closest to the delivery, i.e., the day of delivery or in the 7 d after delivery. Alcohol and tobacco use were recorded only after 2005, and data on concomitant medications were not available in the cohort.

All ART combinations administered during pregnancy were recorded, with the dates when started and stopped. For each drug (called “index drug”), exposure status was categorized as follows: (1) unexposed to the index drug, but exposed to other drugs (control group), (2) exposed to the index drug since conception or the first trimester, or (3) exposed to the index drug only since the second or third trimester. Another categorization was used in sensitivity analyses concerning only first-trimester exposure: (1) unexposed to any ART in the first trimester, i.e., ART was initiated during second or third trimester (control group), (2) exposed to the index drug in the first trimester, (3) exposed to another drug in the first trimester of pregnancy. Since 1994, the standard of care changed from zidovudine monotherapy (1994–1996), to dual nucleoside reverse transcriptase inhibitors (NRTIs) (1997–1999), to triple-combination drug regimens (selected patients for 2000–2004, and all pregnant women after 2004). We tested 18 ARV drugs for the analysis on overall birth defects and three combinations of drugs: any NRTI, any non-nucleoside reverse transcriptase inhibitor (NNRTI), and any protease inhibitor (PI).

Neonatal variables used in the analysis included gender, gestational age, birth weight, and HIV infection status.

Statistical Analysis

The prevalence of birth defects was estimated and compared according to various maternal and neonatal characteristics, using the χ2 test and Fisher's exact test, as appropriate.

We first studied associations between overall birth defects and each ARV drug using univariate and multivariate logistic regression. Multivariate models included IDU, geographical origin, maternal age, and maternity center. These variables were selected because they were used in the literature and were available for the whole study period. Year of birth was not included in the main analyses because of collinearity with prevention of mother-to-child transmission (PMTCT) strategies; however, it was adjusted for in sensitivity analyses. Alcohol and tobacco use could not be included as adjustment variables because they were not available for the whole study period.

We then studied specific associations between birth defects by organ system and (1) efavirenz, zidovudine, didanosine, and nelfinavir, on the basis of prior studies, and (2) any other ARV drugs associated with overall birth defects at p≤0.20 in previous multivariate analysis (these drugs being zalcitabine, lamivudine, emtricitabine, any NNRTI, and indinavir). In order to evaluate the independent effects of drugs often used in combinations, such as zidovudine with lamivudine, we also adjusted for all drugs found to be associated with the type of birth defect under consideration, with a univariate p≤0.10, in either the EUROCAT or the MACDP classification.

For each drug considered, the primary analysis compared neonates exposed in the first trimester and those exposed during the second or third trimester with neonates not exposed to the drug during the whole pregnancy (control group). Women with missing data for any adjustment variables were excluded from multivariate analysis, since they did not exceed 2% of the study population for each variable. Correction for multiple comparisons was not performed because the analyses were based on hypotheses emanating from previous findings in the literature and the robustness of the findings of the current study.

Several sensitivity analyses were conducted: (1) exclusion of IDU, (2) inclusion of TOPs and stillbirths, (3) not considering birth defects diagnosed beyond the first week or 6 mo postnatally, (4) using alternative categories for ART exposure status (unexposed to any ART in the first trimester as control group), (5) excluding infants exposed to more than one combination of ART during pregnancy, (6) using more or less parsimonious multivariate models and, particularly, including year of birth, CD4 cell count, or maternal viral load closest to delivery as adjustment variables.

A two-sided p<0.05 was taken as indicating statistical significance. Data were analyzed using Stata 11.0 software (Stata Corp) [26]. No adjustment was used for multiple testing.

For each ARV drug, we calculated the power to detect an association between overall birth defects and first-trimester exposure (compared with no exposure during pregnancy). Power to show an odds ratio (OR) of 1.5 was >85% for zidovudine, lamivudine, ritonavir, and lopinavir, and was >70% for didanosine, stavudine, abacavir, tenofovir, and nevirapine (data shown in Table 2). For all these drugs, power was >95% to detect an OR of 2.


Results

The analysis was conducted in 13,124 live-born children, born between 1 January 1994 and 31 December 2010, among whom 42% (n = 5,388) were exposed to ART in the first trimester of pregnancy. PMTCT strategies varied over time, and the proportion of infants exposed to ART in the first trimester increased from 19% in 1994–1996 to 52% in 2005–2010. The evolution in time of types of treatment and trimesters of exposure are presented in Table 3. The median maternal age was 31 y, most women were from sub-Saharan Africa (61%) and parous (62%), and very few were intravenous drug users (2%). Most women had a good immunovirological status (CD4≥350 cells/ml and viral load <400 copies/ml; Table 4). Data at birth was collected for the newborns of all women enrolled. Median follow-up of children was 19 mo (interquartile range 12–24 mo).

Overall Birth Defects

The overall birth defect rate was 4.4% (95% CI 4.0%–4.7%) (n = 575/13,124), according to the EUROCAT classification and 7.0% (95% CI 6.5%–7.4%) (n = 914/13,124) according to the MACDP classification. The rate increased from 1994–1996 to 1997–1999 and then decreased slightly afterwards. The presence of a birth defect was significantly associated with male gender and higher maternal age. Neonates with birth defects were more frequently born by cesarean section, preterm, and with low birth weight (Table 4).

Associations with ARV drugs are presented using the EUROCAT classification, and studied in sensitivity analyses for the MACDP classification. Using the EUROCAT classification, overall birth defects were significantly associated with zidovudine in the first trimester, compared with no zidovudine during pregnancy (5.1% for n = 3,267 children exposed in the first trimester versus 4.0% for n = 2,152 children not exposed to zidovudine, AOR = 1.39 [95% CI 1.06–1.83], p<0.05), as well as with didanosine (6.3%, n = 927, for first-trimester exposure versus 4.3%, n = 11,651, for unexposed, AOR = 1.44 [95% CI 1.08–1.92], p = 0.02), lamivudine (5.0%, n = 3,772, for first-trimester exposure versus 4.0%, n = 3,734, for unexposed, AOR = 1.37 [95% CI 1.06–1.76], p = 0.02) and indinavir (7.7%, n = 350, for first-trimester exposure versus 4.3, n = 12,492, for unexposed, AOR = 1.66 [95% CI 1.09–2.53], p = 0.03) (Figure 2; Table 2). Defects according to the MACDP classification were associated with the same four drugs, as well as with zalcitabine (AOR = 2.16 [95% CI 1.17–4.00], p = 0.01) and any kind of NNRTI (AOR = 1.33 [95% CI 1.07–1.66], p = 0.03) (Table 5). These associations were independent of IDU, geographical origin, maternal age, and maternity center.

Birth Defects by Organ System

Exposure to efavirenz during the first trimester was not found to be associated with birth defects overall in the EUROCAT classification (5.4%, n = 20/372, AOR = 1.16 [95% CI 0.73–1.85], p = 0.70) (Figure 2; Table 2). However, there was a statistically significant association between neurological birth defects and efavirenz in the first trimester in the secondary analysis using the modified MACDP classification (1.1% among 372 children exposed to efavirenz in the first trimester versus 0.4% among 12,729 children unexposed, AOR = 3.0 [95% CI 1.1–8.5], p = 0.04, absolute risk difference +0.7% [95% CI +0.07%; +1.3%]) (Table 6). This association did not reach significance in the primary analysis using the EUROCAT classification (AOR = 2.1 [95% CI 0.7–5.9], p = 0.16). The four neurological defects, according to MACDP, reported in children exposed to efavirenz in the first trimester were ventricular dilatation with anomalies of the white substance, partial agenesis of the corpus callosum, subependymal cyst, and pachygyria. Congenital infection or associated non-neurological defects were not reported for these four children. Efavirenz was not associated with other birth defects.

Exposure to zidovudine during the first trimester was associated with CHDs according to the EUROCAT classification (2.3% among the 3,267 children exposed to zidovudine in the first trimester versus 1.1% among the 2,152 children unexposed to zidovudine, AOR = 2.2 [95% CI 1.3–3.7], p = 0.003) (Table 6). The absolute risk difference attributed to zidovudine was therefore +1.2% (95% CI +0.5; +1.9%). CHDs according to EUROCAT classification were also associated with zalcitabine, lamivudine, and indinavir in the univariate analysis, but after adjustment for other concomitant ARV drugs, the association did not reach significance. Six children exposed to emtricitabine during the second or third trimester were diagnosed with a CHD (5.1%, n = 6/118, versus 1.4% among the 12,420 children unexposed to emtricitabine, AOR = 4.5 [95% CI 1.9–10.9], p = 0.001), but four of them were also exposed to zidovudine during the first trimester. The association between zidovudine and heart defects remained the same when (1) limited to diagnoses made in the first 6 mo or in the first week of life, or to infants exposed to only one combination of ART during pregnancy, (2) adjusted for prematurity, parity, CD4 count, year of birth, and gender (AOR for zidovudine = 2.2 [95% CI 1.3–3.6], p = 0.003), (3) using alternate categorization for zidovudine exposure (AOR = 2.1 [95% CI 1.3–3.6], p = 0.003, for zidovudine in the first trimester versus no treatment at all during the first trimester), (4) using the MACDP classification (Table 6), and (5) including TOPs and stillbirths. Zidovudine was not found to be associated with other types of birth defects. In the largest multivariate model cited above, the other variables significantly associated with CHDs were maternal age >35 y, prematurity (AOR = 2.5 [95% CI 1.7–3.6]), female gender (AOR = 1.4 [95% CI 1.0–2.0]), and CD4 count <200 cells/ml (AOR = 1.7 [95% CI 1.1–2.7] versus CD4>350 cells/ml). Time period was not independently associated with heart defects (p = 0.23). Among the 74 children with a diagnosis of CHD and exposed to zidovudine during the first trimester, the most frequent heart defects were ventricular septal defects (n = 43), atrial septal defects (n = 13), and persistence of the ductus arteriosus (n = 9). We found no significant association between heart defects and any of the other ARV drugs included in the multivariate model, which were lamivudine, zalcitabine, emtricitabine, and indinavir. No interaction was found between zidovudine and lamivudine.

Head and neck defects, as described in the EUROCAT guidelines [22],[23], were associated with didanosine (0.5%, n = 5/927, for first-trimester exposure versus 0.2%, n = 18/11,651, in the unexposed group, AOR = 3.4 [95% CI 1.1–10.4], p = 0.04) and with indinavir (0.9%, n = 3/350, in the exposed versus 0.2%, n = 22/12,470, in the unexposed group, AOR = 3.8 [95% CI 1.1–13.8], p = 0.04) (Table 6). Didanosine and indinavir were prescribed to 6.9% and 3% of the women in the study in the last 6 y, respectively.

The association between birth defect by organ system and each ARV drug is described in Table 7. All birth defects among live births are listed Table 8, and birth defects among TOP are listed in Table 9. We found no association between exposure to other ARV drugs and overall birth defects or specific birth defects, including for tenofovir, with 823 children exposed in the first trimester: AOR = 0.75 (95% CI 0.51–1.10), with a power of 72% for an OR of 1.5 (Table 2).


Discussion

The prevalence of birth defects in our study population was 4.4% as assessed using the EUROCAT guidelines and 7% using the MACDP classification. This is higher than the rates reported in most large studies including patients exposed to ARV drugs, which were 1.5% in the European Collaborative Study, published in 2005 and thus including different drugs than those used in more recent studies [18], 2.8% in a recent study in the United Kingdom [17], and 2.9% in the APR [13]. The prevalence in our cohort is, however, consistent with that observed in smaller prospective studies, which all report higher rates, from 5.3% to 8.3% [11],[12],[16],[27]. We hypothesize that studies involving few centers may have a higher level of reporting because of greater motivation of clinicians for the specific research program and more intensive data monitoring than in large multicenter cohort studies and registries. In this sense, the higher prevalence in EPF despite the large number of pregnancies and study sites may result from the high level of completeness of our data collection, which is sustained through regular monitoring at study sites and motivated clinicians uniting in an active national network, but may also result from easier referral for free further investigations, facilitated by the French health insurance system.

An important result is that no association was found between birth defects and lopinavir or ritonavir with a power >80% for an OR of 1.5, and for tenofovir, nevirapine, and abacavir with a power >70%. For all these drugs, the power was >95% for an OR of 2. This result is very reassuring in view of the fact that several of these ARV drugs are currently being increasingly used.

We found a specific association between exposure to zidovudine during the first trimester and CHDs, for both classifications. It persisted after adjusting for potential confounding variables, including other ARV drugs, and in all sensitivity analyses, including adjustment for year of birth. The association with heart defects was of a larger magnitude than that with birth defects overall, and no association was found between zidovudine and other types of defects, suggesting a specific association. We found the same risk factors (maternal age and prematurity) for heart defects as in general population [28],[29], which argues against uncontrolled selection biases. The other risk factors were maternal CD4 count <200 cells/ml and female gender. The association between immune status and heart defects may be due to a direct effect of immune status or to cotrimoxazole, which is recommended in patients with CD4 <200 cells/ml [30] but which has been shown to be associated with birth defects [31][34]. Unfortunately, concomitant medications were not documented in our cohort. Brogly et al. reported more heart defects for children exposed to zidovudine during the first trimester [11] but stressed that this association was based on a small number of defects, and needed further confirmation. Watts et al. described an association between ART and CHDs, but could not incriminate any drug in particular [14]. Finally, zidovudine was found to be associated with heart dysfunction [35]: this association was stronger for females than for males. Similarly, a gender difference regarding heart dysfunction and zidovudine has been described in an animal study [36]. The potential pathological mechanism has yet to be elucidated. Other studies on birth defects did not find the same association, but most of them lacked statistical power since the numbers of children included were between 344 [37] and 8,242 [17]. The APR, the only previous study with a number of patients similar to that of our study, was not designed as a cohort study and includes data collected from different countries with highly diverse follow-up protocols, which may lead to classification and selection biases [13]. The strength of our prospective cohort in this respect is the free access for all pregnant women in France to standardized prenatal and postnatal evaluations, according to national guidelines, including detailed fetal ultrasound in each of the three trimesters of pregnancy, and meticulous examination at birth and at follow-up visits through the age of 2 y by a pediatrician. We are aware that the prevalence of CHDs may be overestimated in our cohort compared to population studies [29],[38], as they were adjudicated by general pediatricians and not heart defect specialists, as done in some other HIV studies [13],[17]. However this possible overestimation should not lead to differential misclassification bias in the association between these defects and zidovudine, since there was no alert for such risk at the time of the study. The adjudication method was homogeneous throughout our cohort, and, in particular, echocardiograms were performed in children only if there was an anomaly during routine prenatal ultrasound screening or if clinical symptoms such as a heart murmur were present during routine clinical examination. Thus, there was no guideline to perform cardiac evaluations specifically in infants exposed to zidovudine. According to new World Health Organization (WHO) recommendations [39] and current practices in European countries, exposure to zidovudine during pregnancy should decrease in the future, but it remains important to continue investigation into the effects of this drug to evaluate potential consequences for development for the large number of children exposed in the past to this drug.

We found a significant association between exposure to efavirenz during the first trimester and neurological defects, using the MACDP classification: AOR = 3.0 (95% CI 1.1–8.5). This association did not reach significance using the EUROCAT classification (AOR = 2.5 [95% CI 0.9–6.8], p = 0.13) because this classification excluded a case with a subependymal cyst. The neurological defect rate among children exposed to efavirenz in the first trimester was 1.1%. There has been concern about a teratogenic effect because a preclinical study found three birth defects among 20 monkeys exposed to efavirenz [9], and two cases of neural tube defects were reported in humans [40],[41]. Recently, two studies found an association between efavirenz and birth defects in general [11],[12], with a high prevalence of birth defects (12.8% and 15.6%) among children exposed to efavirenz in the first trimester (47 and 32 children, respectively, for [11] and [12]). The updated APR reported a prevalence of 2.3% among 766 children exposed during the first trimester, not different from children exposed later (1.9% for 160 children). A meta-analysis including these studies found a relative risk of 0.85 [95% CI 0.61–1.20] among 1,437 women exposed to efavirenz in the first trimester compared to non-efavirenz-based regimens [10]. There are two difficulties in studying this association in high-income countries, where detailed studies of birth defects are feasible. First, because the use of efavirenz was, until recently, discouraged in pregnant women and women planning to become pregnant, the number of exposed fetuses is relatively small, and power is lacking. With 372 children exposed to efavirenz in the first trimester, our study is larger than any prospective cohort studies to date. Second, detailed ultrasound examination is recommended, which presumably would lead to the detection of major birth defects early in pregnancy, thus allowing for TOP before inclusion in perinatal studies. The possible non-inclusion of patients with fetuses with major defects because of early TOPs may explain why the association was lower, using the EUROCAT classification, which includes only major defects. Efavirenz is efficacious and inexpensive and is consequently widely prescribed worldwide. Recent guidelines from the US Department of Health and the WHO state that efavirenz does not necessarily need to be changed at the beginning of pregnancy [39],[42]. Our findings are less reassuring, but no causal association can be concluded, because of the small number of defects, and especially since the different neurological anomalies reported do not correspond to a specific malformative pathway.

Didanosine was associated with head and neck defects, whatever the classification. A higher risk of birth defects for children exposed to didanosine has also been reported in the APR, but not in other studies [13]. Our study has the greatest number of children exposed to didanosine during the first trimester, and thus the discrepancy between our results that those of other studies could be due to lack of power in the other studies.

Nevertheless, didanosine is no longer recommended and is not commonly prescribed during pregnancy (6.9% over the last 5 y in EPF).

Finally, a significant association was found between indinavir and head and neck defects. Birth defects associated with PIs have been less studied, because the placental transfer is low. Nevertheless, an increased risk of birth defects was reported in rats exposed to indinavir [43]. As is the case for didanosine, indinavir is no longer prescribed (less than 3% in the last 5 y). For both of these drugs, the absolute numbers of defects in the exposed groups were low, leading to large confidence intervals, reinforcing cautiousness in any causal conclusion.

There is no nationwide description of the birth defect rate in the French general population, but there are exhaustive regional registries. The birth defect rate observed in our study was higher than in the Paris Birth Defect Registry [44]: 4.4% versus 2.3% (p<0.001) among live births, with the same classification (EUROCAT) and during the same period. However, interpretation of this difference is difficult and cannot be attributed solely to treatments and/or HIV infection, because of the longer follow-up of children in our cohort and because of potential confounding factors and regional disparities. The rate of birth defects in our cohort changed over time, with an increase between 1994 and 1996, and a slight decrease afterwards. This decrease is unlikely to be due solely to changes in the general population, since the trend in the birth defect rate among live births in the Paris registry was a regular decrease from 2.4% in 1994–1996 to 2.1% in 2005–2009. We chose not to include time period in the main analysis because of collinearity with PMTCT strategies. However, when included in sensitivity analyses, adjustment for year of birth did not change the association between zidovudine and heart defects.

Strengths and Limitations of the Study

Our study presents many strengths. To our knowledge, it is the largest national cohort of live births among HIV-infected women, with homogeneous prenatal and postnatal follow-up via standardized questionnaires, and thus has higher power than most studies to date, which is reassuring for drugs found to be not associated with birth defects. Women were included prospectively during pregnancy, before any detection of birth defects. Clinical examinations of children were performed during the first 2 y of life, such that it is unlikely that many birth defects were missed. We used the EUROCAT classification, which excludes most minor anomalies and contains very few decision trees, minimizing the need for additional details for classification, which seems to make it more reproducible. We also used the APR-modified MACDP classification in secondary analyses to facilitate comparisons with previous studies. We studied birth defects by organ system, which is a more specific approach than considering the overall incidence of birth defects. Indeed, teratogenic agents generally affect particular developmental pathways and not several pathways randomly. Therefore, although the number of defects per organ system is lower than the total number of defects, the power for finding an association can be higher. Finally, many characteristics of the mother and neonate were available for adjustment for potential confounders.

Our study also presents some limitations. Gestational age at inclusion varied over time, and early TOPs were not captured before 2005. We then decided to exclude stillbirths and TOPs from the main analysis. The reasons were to avoid false associations of major defects with drugs prescribed more often in recent years, and to limit underestimation of major defects likely to be detected earlier in pregnancy for efavirenz than for other drugs. In sensitivity analyses including TOPs and stillbirths, as expected, the association remained unchanged for zidovudine with CHDs, but decreased for efavirenz with neurological defects. We also excluded the small group of women not treated with ART, as relevant variables to adjust for this very precarious situation were not available in the EPF study. Another concern is the risk of false positive associations due to multiple testing. We chose not to perform adjustments for multiple testing because such an approach is questionable for exploratory studies such as this from a methodological standpoint [45]. Additionally, most statistical tests were not significant, and for significant associations, our discussion was based both on (1) hypotheses emanating from previous findings in the literature and (2) the robustness of the findings of the current study, which was important for the association between zidovudine and heart defects. Lastly, we were cautious in any causal interpretation. Except for the interaction of zidovudine with other drugs, we did not address other possible interactions because of the number of possible combinations, and hence potential interaction effects, and the lack of previous literature to guide the analyses. Missing data were excluded as they were rare for most maternal covariates, except for viral load and CD4 cell count, which were not measured routinely before 1996. These covariates were not likely to be related to birth defect detection and reporting.

Another limitation, common to most studies of birth defects and ART, is the lack of data on concomitant medication and alcohol and tobacco use, which in the case of the current study were not available for the whole study period. Cotrimoxazole use was indirectly accounted for by adjusting for CD4 cell counts in sensitivity analyses. Exposure to tobacco and alcohol during pregnancy was reported by 5% and 1.9% of women, respectively, between 2005 and 2010. Whatever their impact on birth defects, these factors were unlikely to be related to the prescription of any particular ARV drug, and thus should not bias the results.

Conclusions

In conclusion, we found a higher rate of CHDs in children exposed in utero to zidovudine, which should be taken into consideration, given the large number of children exposed to perinatal zidovudine in the world. Potential mechanisms underlying this association must be investigated. This alert reinforces recent recommendations for PMTCT, which no longer consider zidovudine to be the first-line ART during pregnancy [39]. Though the higher rate of neurological birth defects observed in infants exposed to efavirenz in the first trimester must be interpreted with caution, as discussed previously, our results reinforce the importance of careful clinical follow-up of children in case of perinatal exposure to efavirenz, as recommended in the WHO guidelines [39]. In our study, ventricular dilatation, partial agenesis of the corpus callosum with an interhemispheric cyst, pachygyria, and subependymal cyst, detected by routine prenatal ultrasound screening and/or clinical postnatal follow-up, may have been missed by neonatal examination only. The absence of association between birth defects and several ARV drugs that are increasingly prescribed during pregnancy, such as tenofovir, which is the first-line WHO recommendation for PMTCT, is reassuring and may encourage us to explore various zidovudine-sparing regimens. Nonetheless, whatever the impact some ARV drugs may have on birth defects, it is largely surpassed by the major role of ART in successful PMTCT, leading to the decrease of transmission rates from 20% without ART to the current rate of less than 1%.


We are indebted to all families who agreed to participate and thank all the centers participating in EPF.

Active contributors of current clinical centers participating in EPF (the asterisks indicate the main investigator of each clinical site): Assistance Publique–Hôpitaux de Paris (APHP) Hôpital Louis Mourier, Colombes, France (Laurent Mandelbrot*, Françoise Meier, Dominique Duro, Marine Joras, Emmanuel Mortier, Catherine Crenn-Hebert, Corinne Floch-Tudal*, Fabienne Mazy); APHP Hôpital Beaujon, Clichy, France (Mariam Bensalah, Agnès Villemant-Uludag, Agnès Lefort, Virginie Zarrouk, Pierre-François Ceccaldi*); Hôpital Sainte Musse, Toulon, France (Gilles Hittinger*); Centre Hospitalier Général (CHG) Marechal Joffre, Perpignan, France (Martine Malet, Bruno Bachelard, Marie Medus*); Centre Hospitalier Universitaire (CHU) Caremeau, Nîmes, France (Joëlle Dendale-Nguyen*); Centre Hospitalier Départemental les Oudairies, La Roche sur Yon, France (Jean-Pierre Brossier, Olivier Aubry, Jean-Luc Esnault, Sophie Leautez, Philippe Perré*); Centre Hospitalier William Morey, Châlon sur Saone, France (Sandrine-Anne Martha*); Centre Hospitalier, Vernon, France (Mahfoud Rouha); Centre Hospitalier Intercommunal de Cornouaille, Quimper, France (Pascale Perfezou*, Gilles Blondin, Charles Bellot); Centre Hospitalier Universitaire, Brest, France (Séverine Ansart*, Philippe Le Moine, Karine Bages-Jaffuel, Michel Garré, Sylvain Jaffuel); Centre Hospitalier, Saint-Brieuc, France (Corinne Daniel*, Christian Calvez, Claude Beuscart, Emmanuelle Boutaric, Jennifer Rohan, Sylvie Lemoal); Centre Hospitalier Universitaire, Rennes, France (Linda Lassel, Ghislaine Cotten, Christelle Dupré, Esther Beauville, Cédric Arvieux*); Centre Hospitalier Bretagne Atlantique, Vannes, France (Anabèle Dos Santos*, Corinne Cudeville, Yves Poinsignon, Virginie Mouton-Rioux, Gaétane Mousset, Anne Grellier); Centre Hospitalier de Bretagne Sud, Lorient, France (Philippe Moreau, Philippe Tillaut, Virginie Mouton-Rioux, Odile Luycx-Vaillant, Philippe de Morel, Marie-Françoise Le Coz, Isabelle Belzic, Mathilde Niault*); Centre Hospitalier de la Région d'Annecy, Annecy, France (Anne Vandenbergh, Cécile Janssen, Susanne Braig, Virginie Vitrat*, Jacques Gaillat, Gaëlle Clavere, Jean-Pierre Bru, Blandine Peyret); Centre Hospitalier Intercommunal, Montfermeil, France (Catherine Mullard, Marie Echard, Philippe Talon*, Marion Dehlinger); Centre Hospitalier Intercommunal, Montreuil, France (Cécile Winter, Brigitte Heller-Roussin*); APHP Hôpital Cochin-Port Royal, Paris, France (Odile Launay, Maria Fouchet, Ghislaine Firtion*, Isabelle Goupil, Emmanuelle Pannier*, Nora Boudjoudi); APHP Hôpital Bichat, Paris, France (Marylène Bodard, Valérie Vivier, Mandovi Rajguru, Virginie Huri, Elie Azria, Sophie Matheron*, Neila Elaoun); Centre Hospitalier Intercommunal, Créteil, France (Valérie Garrait*, Christiane Komme, Laurent Richier, Claudine Touboul); Hôpital de la Croix Rousse, Lyon, France (Valérie Thoirain, Laurent Cotte*, Olivier Tariel, Joseph Koffi, Jean-Marc Labaune, Corinne Brochier); Centre Hospitalier Pellegrin, Bordeaux, France (Denis Roux*, Christophe Elleau, Camille Runel*); CHU Les Abymes, Pointe à Pître, France (Henri Bataille*, Marie-Thérèse Sow, Ketty Samar, Blandine Muanza); Centre Hospitalier Général, Creil, France (Marc Duval*, Clarisse Kingue-Ekollo, Bénédicte Carpentier); Centre Hospitalier Intercommunal (CHI) la Seyne sur Mer, La Seyne sur Mer, France (Isabelle Ronda, Jean-Marc Chamouilli*); Hôpital de Haute Pierre, Strasbourg, France (Natacha Entz-Werle); Centre Hospitalier Général, Longjumeau, France (Hervé Seaume*, Sarah Ducrocq, Yvon Lemercier); Hôpital Paule de Viguier, Toulouse, France (Joëlle Tricoire*, Alain Berrebi*, Michèle Antras, Evelyne Armand); Centre Hospitalier de la Côte Basque, Bayonne, France (Claudine Cayla, François Bonnal, Catherine Chabanier); Centre Hospitalier Intercommunal, Villeneuve-Saint-Georges, France (Isabelle Matheron, Anne Chacé); Centre Hospitalier Intercommunal, Poissy Saint Germain en Laye, France (Sophie Couderc, Anne Boutemy*); Centre Hospitalier Général, Fontainebleau, France (Marie-Christelle Dallot, Alain Al-Issa, Corinne Routier*); Centre Hospitalier Robert Ballanger, Aulnay, France (Ahmed Zakaria, Véronique Favret, Juliette Gerbe, Elisabeth Questiaux); Hôpital Civil, Strasbourg, France (MariaLuisa Partisani*, David Rey, Christine Cheneau); Centre Hospitalier Victor Dupouy, Argenteuil, France (Christine Allisy, Dominique Brault*); APHP Hôpital Tenon, Paris, France (François Hervé, Marie-Gisèle Lebrette*, Lise Selleret); Centre Hospitalier Général, Saint-Denis, France (Dieudonné Ekoukou, Pascal Bolot*, Marie-Aude Khuong-Josses, Marie-Christine Allemon, Nelly Ghibaudo); APHP Hôpital Necker, Paris, France (Pierre Frange, Christine Rouzioux, Florence Veber, Stéphane Blanche*, Delphine Lemercier*, Marie-Christine Mourey); Centre Hospitalier Sud Francilien, Evry Corbeil, France (Gilles Blasquez); Centre Hospitalier Sud Francilien, Evry Corbeil, France (Michèle Granier*, Rose Nguyen, Alain Devidas*); Centre Médico-Chirurgical et Obstétrical, Schiltigheim, France (Israël Nisand, Michèle Weil, Christophe Vayssière); Centre Hospitalier Régional (CHR) American Memorial Hospital, Reims, France (Jean-Luc Berger, Martine Munzer*, Olivier Graesslin); APHP Groupe Hospitalier Pitié Salpêtrière, Paris, France (Anne-Florence Alix-Naime, Roland Tubiana*, Frédérique Quetin, Anne Laubies, Manuela Bonmarchand, Jennifer Sommer, Patricia Bourse); Centre Hospitalier René Dubos, Pontoise, France (Anne Coursol*, Michel Youssef); APHP Hôpital Béclère, Clamart, France (Mariem Raho, Véronique Chambrin*, Philippe Labrune*, Laure Clech, Alexandra Benachi); Centre Hospitalier Marc Jacquet, Melun, France (Bertrand Le Lorier*, Isolde Pauly-Ravelly); Centre Hospitalier Général, Evreux, France (Claude Allouche, Ama Johnson*); APHP Hôpital Jean Verdier, Bondy, France (Laurence Benoist, Catherine Delannoy, Eric Lachassine, Stéphanie Bolie, Joël Gaudelus, Vincent Jeantils, Amelie Benabara*); Centre Hospitalier de Meaux, Meaux, France (Leïla Karaoui*, Véronique Lefèvre); CHU de l'Archet, Nice, France (André Bongain*, Eliane Galiba, Anne Deville, Fabrice Monpoux*, Jacques Durant); Centre Hospitalier François Quesnay, Mantes La Jolie, France (Jean Furioli, Jean-Louis Salomon, Françoise Granier, Antoine Doumet*); CHU Hôpital Nord, Amiens, France (Youssef Douadi, Jean Gondry, Jean-Luc Schmit*, Brigitte Pautard); Hôpital de la Conception, Marseille, France (Marc Gamerre, Ludovic Cravello*, Isabelle Thuret*); CHU de Brabois-Hôpital des Adultes, Vandoeuvre les Nancy, France (Laurence Neimann, Claire Hubert*); APHP Hôpital Trousseau, Paris, France (Bruno Carbonne*, Geneviève Vaudre, Marie-Dominique Tabone, Catherine Dollfus*); Hôpital Charles Nicolle, Rouen, France (Didier Pinquier, Gaëlle Pinto Cardoso*, Brigitte Clavier, Françoise Borsa-Lebas); APHP Hôpital Robert Debré, Paris, France (Agathe De Lauzanne, Constance Borie, Sandrine Leveillé, Albert Faye*, Erianna Bellaton, Dominique Garion, Martine Levine*); APHP Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (Claire Colmant, Cécile Goujard, Marc Tardieu, Ikram Jrad, Delphine Peretti*, Katia Bourdic, Corinne Fourcade*); Centre Hospitalier Régional Universitaire (CHRU) Hôpital Saint Jacques, Besançon, France (Catherine Chirouze, Jean-Marie Estavoyer*, Robert Maillet); CHU de Nantes, Nantes, France (Véronique Reliquet*, Norbert Winer, Cécile Brunet*); CHRU Hôpital du Bocage, Dijon, France (Isabelle Reynaud*, Claire Briandet); CHRU Hôpital Clemenceau, Caen, France (Jacques Brouard*, Gaël Beucher, Pascale Goubin); Centre Hospitalier de Lagny, Lagny, France (CécileLanty, Eric Froguel, Arnaud Chalvon Demersay*, Gilbert Algava); Hôpital André Mignot, Le Chesnay, France (Véronique Hentgen*, Fabienne Messaoudi); CHRU de Tours, Tours, France (Louis, Bernard*, Pascale Nau, Jérôme Potin); Institut d'Hémato-Oncologie Pédiatrique, Lyon, France (Nadine Taché, Yves Bertrand, Kamila Kebaïli*); Hôpital Nord, Saint Etienne, France (Véronique Ronat, Anne Fresard, Kareen Billiemaz*); Centre Hospitalier Général, Bastia, France (Ramona Abrudan*); Centre Hospitalier Universitaire, Angers, France (Alain Fournié, Jean-Marie Chennebault*); Centre Hospitalier Régional, Orléans, France (Philippe Arsac*); APHP Hôpital Lariboisière, Paris, France (Nicole Ciraru-Vigneron*, Geneviève Mouchnino, Dominique Ayral); CHR Arnaud de Villeneuve, Montpellier, France (Nelly Guigue, Muriel Lalande*); Centre Hospitalier Général, Orsay, France (Christiane De Gennes*, Sonia Chanzy, Valérie Isart); Centre Hospitalier de Saint Martin, Saint Martin, France (François Cazassus, Véronique Walter, François Bissuel*); CHR Jeanne de Flandres, Lille, France (Yamina Hammou*, Sophie d'Angelo, Faïza Ajana, Françoise Mazingue*); CHU Maison de la Femme et de l'Enfant, Fort de France, France (Raymond Mezin, Yves Hatchuel*, André Cabié).

Clinical centers that contributed in the past to EPF: CHRU de Dourdan, Dourdan; CHG de Gonesse, Gonesse; Hôpital Max Fourestier, Nanterre; APHP Hôpital Hôtel Dieu, Paris; Hôpital d'Aix en Provence, Aix en Provence; CHI Jean Rostand, Sèvres; Centre Hospitalier de Neuilly, Neuilly sur Seine; APHP Hôpital Saint-Antoine, Paris; Centre Médico-Chirurgical Foch, Suresnes; Hôpital Esquirol, Saint-Maurice; Institut Mutualiste Montsouris, Paris; Clinique du Blanc Mesnil, Blanc Mesnil; Hôpital des Métallurgistes, Paris; APHP Hôpital Avicennes, Bobigny; Centre Hospitalier Victor Jousselin, Dreux; APHP Hôpital Boucicaut, Paris; Hôpital Saint Michel, Paris; Hôpital Jean Rostand, Ivry; Hôpital Hôtel Dieu, Lyon; Hôpital Saint Claude, Basse Terre; CHG des Feugrais, Elbeuf; APHP Hôpital Ambroise Paré, Boulogne Billancourt; APHP Hôpital Paul Brousse, Villejuif; Centre Hospitalier Louis Domergues, La Trinité; Centre Hospitalier Saint Joseph, Paris.

Steering committee of EPF: Stéphane Blanche, Naïma Bouallag, Nelly Briand, Sandrine Delmas, Catherine Dollfus, Albert Faye, Jérôme Le Chenadec, Laurent Mandelbrot, Christine Rouzioux, Jeanne Sibiude, Jean-Paul Teglas, Roland Tubiana, Josiane Warszawski.

Coordinating center of EPF: INSERM U1018, Centre de Recherche en Épidémiologie et Santé des Populations, Le Kremlin-Bicêtre: Souad Belaggoun, Naïma Bouallag, Leïla Boufassa, Nelly Briand, Sandrine Delmas, Céline Ferey, Paulette Huynh, Julie Lamarque, Corinne Laurent, Jérôme Le Chenadec, Jacques Ngondi, Marlène Pérès, Anaïs Perilhou, Marine Pytkowski, Elisa Ramos, Jean-Paul Teglas, Thierry Wack, Josiane Warszawski.


References
1. Warszawski J,, Tubiana R,, Le Chenadec J,, Blanche S,, Teglas JP,, et al. (Year: 2008) Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS22: 289–29918097232
2. European Collaborative Study (Year: 2005) Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis40: 458–46515668871
3. Cooper ER,, Charurat M,, Mofenson L,, Hanson IC,, Pitt J,, et al. (Year: 2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr29: 484–49411981365
4. Delfraissy JF (2004) Prise en charge thérapeutique des personnes infectées par le VIH. Rapport 2004. Recommandations du groupe d'experts. Paris: Flammarion Médecine-Sciences.
5. Blanche S,, Tardieu M,, Benhammou V,, Warszawski J,, Rustin P,, et al. (Year: 2006) Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS20: 1685–169016931932
6. Thorne C,, Newell ML, (Year: 2007) Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?Drug Saf30: 203–21317343429
7. Briand N,, Mandelbrot L,, Le Chenadec J,, Tubiana R,, Teglas JP,, et al. (Year: 2009) No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS23: 1235–124319424054
8. Jao J,, Abrams EJ, (Year: 2013) Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants. Pediatr Infect Dis J E-pub ahead of print. doi:10.1097/INF.0000000000000224.
9. Bristol-Myers Squibb Company (2006) Sustiva (efavirenz) capsules and tablets leaflet. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021360s014lbl.pdf Accessed 6 July 2013.
10. Ford N,, Calmy A,, Mofenson L, (Year: 2011) Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS25: 2301–230421918421
11. Brogly SB,, Abzug MJ,, Watts DH,, Cunningham CK,, Williams PL,, et al. (Year: 2010) Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J29: 721–72720539252
12. Knapp KM,, Brogly SB,, Muenz DG,, Spiegel HM,, Conway DH,, et al. (Year: 2012) Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J31: 164–17021983213
13. Antiretroviral Pregnancy Registry Steering Committee (2013) The Antiretroviral Pregnancy Registry: interim report—1 January 1989 through 31 July 2013. Available: http://www.apregistry.com/forms/interim_report.pdf Accessed 27 January 2014.
14. Watts DH,, Huang S,, Culnane M,, Kaiser KA,, Scheuerle A,, et al. (Year: 2011) Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med39: 163–17021142844
15. Floridia M,, Mastroiacovo P,, Tamburrini E,, Tibaldi C,, Todros T,, et al. (Year: 2013) Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001–2011. BJOG120: 1466–147523721372
16. Fernandez Ibieta M,, Ramos Amador JT,, Bellon Cano JM,, Gonzalez-Tome MI,, Guillen Martin S,, et al. (Year: 2009) Birth defects in a cohort of uninfected children born to HIV-infected women. An Pediatr (Barc)70: 253–26419246263
17. Townsend CL,, Willey BA,, Cortina-Borja M,, Peckham CS,, Tookey PA, (Year: 2009) Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS23: 519–52419165088
18. Patel D,, Thorne C,, Fiore S,, Newell ML, (Year: 2005) Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women?J Acquir Immune Defic Syndr40: 116–11816123696
19. Newschaffer CJ,, Cocroft J,, Anderson CE,, Hauck WW,, Turner BJ, (Year: 2000) Prenatal zidovudine use and congenital anomalies in a medicaid population. J Acquir Immune Defic Syndr24: 249–25610969349
20. Yeni P, editor(2006) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts.: Flammarion, Médecine-Sciences.
21. Mayaux MJ,, Teglas JP,, Blanche S, (Year: 2003) Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr34: 338–34314600581
22. EUROCAT (2005) EUROCAT Guide 1.3 and reference documents. Instructions for the Registration and Surveillance of Congenital Anomalies. Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf last accessed 01/27/2014
23. EUROCAT (2012) Coding of EUROCAT Subgroups of Congenital Anomalies (Version 2012). Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf last accessed 01/27/2014
24. MACDP (2007) Birth Defects and Genetic Diseases Branch 6-digit code for Reportable Congenital Anomalies.Available at: http://www.cdc.gov/ncbddd/birthdefects/documents/MACDPcode0807.pdf last accessed 01/27/2014
25. Scheuerle A,, Tilson H, (Year: 2002) Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf11: 465–47512426931
26. StataCorporation (2009) Stata 11.0 for Windows. College Station, Texas: Stata Corporation
27. Joao EC,, Calvet GA,, Krauss MR,, Freimanis Hance L,, Ortiz J,, et al. (Year: 2010) Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr53: 176–18520104119
28. Du ZD,, Roguin N,, Barak M,, Bihari SG,, Ben-Elisha M, (Year: 1996) High prevalence of muscular ventricular septal defect in preterm neonates. Am J Cardiol78: 1183–11858914891
29. Laas E,, Lelong N,, Thieulin AC,, Houyel L,, Bonnet D,, et al. (Year: 2012) Preterm Birth and Congenital Heart Defects: A Population-based Study. PediatricsOct;1304: e829–37
30. Yeni P (2010) Prise en charge médicale des personnes infectées par le VIH: rapport 2010—Recommandations du groupe d'experts. Paris: La Documentation Française.
31. Czeizel AE,, Rockenbauer M,, Sorensen HT,, Olsen J, (Year: 2001) The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol15: 637–64611738517
32. Forna F,, McConnell M,, Kitabire FN,, Homsy J,, Brooks JT,, et al. (Year: 2006) Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev8: 24–3616736949
33. Jungmann EM,, Mercey D,, DeRuiter A,, Edwards S,, Donoghue S,, et al. (Year: 2001) Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?Sex Transm Infect77: 441–44311714944
34. Richardson MP,, Osrin D,, Donaghy S,, Brown NA,, Hay P,, et al. (Year: 2000) Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol93: 215–21711074147
35. Lipshultz SE,, Shearer WT,, Thompson B,, Rich KC,, Cheng I,, et al. (Year: 2011) Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol57: 76–8521185505
36. Desai VG,, Lee T,, Moland CL,, Branham WS,, Mittelstaedt RA,, et al. (Year: 2012) Evaluation of hepatic mitochondria and hematological parameters in zidovudine-treated B6C3F(1) mice. AIDS Res Treat2012: 31769522545210
37. Ekouevi DK,, Coffie PA,, Ouattara E,, Moh R,, Amani-Bosse C,, et al. (Year: 2011) Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr56: 183–18721084995
38. Houyel L,, Khoshnood B,, Anderson RH,, Lelong N,, Thieulin AC,, et al. (Year: 2012) Population-based evaluation of a suggested anatomic and clinical classification of congenital heart defects based on the International Paediatric and Congenital Cardiac Code. Orphanet J Rare Dis6: 6421968022
39. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html Accessed 27 January 2014.
40. Fundaro C,, Genovese O,, Rendeli C,, Tamburrini E,, Salvaggio E, (Year: 2002) Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS16: 299–30011807320
41. Saitoh A,, Hull AD,, Franklin P,, Spector SA, (Year: 2005) Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol25: 555–55616047034
42. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission (2012) Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available: http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0 Accessed 27 January 2014.
43. Riecke K,, Schulz TG,, Shakibaei M,, Krause B,, Chahoud I,, et al. (Year: 2000) Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology62: 291–30011029147
44. EUROCAT (2012) Prevalence tables. Available: http://www.eurocat-network.eu/accessprevalencedata/prevalencetables Accessed 27 January 2014.
45. Rothman KJ, (Year: 1990) No adjustments are needed for multiple comparisons. Epidemiology1: 43–462081237

Abbreviations
ANRS Agence Nationale de Recherche sur le Sida et les Hepatites
AOR adjusted odds ratio
APR Antiretroviral Pregnancy Registry
ART antiretroviral therapy
ARV antiretroviral
CHD congenital heart defect
EPF French Perinatal Cohort
EUROCAT European Surveillance of Congenital Anomalies
IDU intravenous drug use
MACDP Metropolitan Atlanta Congenital Defects Program
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
OR odds ratio
PI protease inhibitor
PMTCT prevention of mother-to-child transmission
TOP termination of pregnancy
WHO World Health Organization

Figures

[Figure ID: pmed-1001635-g001]
doi: 10.1371/journal.pmed.1001635.g001.
Figure 1  Study population: French Perinatal Cohort (ANRS CO1/CO11).

[Figure ID: pmed-1001635-g002]
doi: 10.1371/journal.pmed.1001635.g002.
Figure 2  Association between overall birth defects and first trimester antiretroviral drug exposure (French Perinatal Cohort [ANRS CO1/CO11]): multivariate analysis.

Squares indicate AORs for exposure in the first trimester versus no exposure to the drug, adjusted on IDU, geographical origin, maternal age, and maternity center. Lines indicate 95% confidence intervals and square areas are proportional to the power for an OR of 1.5. Total number of birth defects = 575/13,124. Numbers for each ARV drug are shown in Table 3.



Tables
[TableWrap ID: pmed-1001635-t001] doi: 10.1371/journal.pmed.1001635.t001.
Table 1  Main studies on ART exposure and birth defects.
Study and Year Time Period ARV Drugs Compared N (Exposed) Percent with BD Conclusion
Knapp [12] 2012 2002–2007 All children 1,112 5.5 Significant difference for EFV
EFV, unexposed 1,055 5.2
EFV, 1st T 47 12.8
EFV, 2nd–3rd T 9 0
APR [13] 2013 1989–2013 All children 15,451 2.9 No difference between 1st T and later exposure for any drug
Any ART, 1st T 6,526 2.9
Any ART, 2nd–3rd T 8,523 2.8
Didanosine, 1st T 416 4.8 Didanosine and nelfinavir have higher rate of BDs than general population
Nelfinavir, 1st T 1,211 3.9
Ford [10] 2011 Until 2011 EFV, 1st T 1,290 2.9 No difference
No EFV 8,122 3.9
Watts [14] 2011 1997–2000 All ARTchildren 1,414 4.2 No difference for overall defects
Any ART, 1st T 636 4.7
Any ART, 2nd–3rd T 778 3.9
Heart defects Significantly more heart defects for exposure in the 1st T
Any ART, 1st T 2.5
Any ART, 2nd–3rd T 0.8
Brogly [11] 2010 1993–2000 All children 2,033 5.3 Significant difference for EFV
Any ART, 1st T 763 5.8
No ART, 1st T 1,270 4.8
EFV, 1st T 32 15.6
No EFV, 1st T 2,001 5.0
Joao [27] 2010 2002–2007 All children 995 6.2 No difference between exposure groups
Any ART, 1st T 242 6.2
Any ART, 2nd T 518 6.8
Any ART, 3rd T 208 4.3
Fernandez [16] 2009 2000–2005 All children 623 8.3 No difference between exposure groups
Any ART, 1st T 8.8
Any ART, 2nd–3rd T 7.4
Townsend [17] 2009 1990–2007 All children 8,242 2.8 No difference between exposure groups
Any ART, 1st T 1,708 3.1
Any ART, 2nd–3rd T 5,427 2.7
No ART 498 2.8
Patel [18] 2005 1986–2003 All children 3,740 1.5 No difference between exposure groups
Any ART, 1st T 789 1.8
Any ART, 2nd–3rd T 1,184 1.4
No ART 1,767 1.4
ART, 1st T
Monotherapy or dual nucleoside 243 1.2 No difference between exposure groups
Combination ART 546 2.0
EFV 19 0.0

BD, birth defect; EFV, efavirenz; T, trimester.


[TableWrap ID: pmed-1001635-t002] doi: 10.1371/journal.pmed.1001635.t002.
Table 2  Association between overall birth defects and antiretroviral drugs (French Perinatal Cohort [ANRS CO1/CO11]).
In Utero Exposure Na Percent with BD Number with BDb ORc 95% CI p-Valued AORe 95% CI p-Valued Powerf
Zidovudine
Unexposed 2,152 4.0 86 1 0.12 1 0.046 88%
1st T 3,267 5.1 165 1.28 0.98–1.67 1.39 1.06–1.83
2nd–3rd T 7,493 4.3 322 1.08 0.85–1.38 1.16 0.90–1.51
Missing 212 0.9 2
Didanosine
Unexposed 11,651 4.3 500 1 0.01 1 0.02 75%
1st T 927 6.3 58 1.49 1.12–1.97 1.44 1.08–1.92
2nd–3rd T 529 3.2 17 0.74 0.45–1.21 0.77 0.47–1.27
Missing 17 0 0
Zalcitabine
Unexposed 13,010 4.4 567 1 0.2 1 0.07 15%
1st T 103 7.8 8 1.85 0.89–3.82 2 0.94–4.25
2nd–3rd T 11 0 0 NA NA
Lamivudine
Unexposed 3,734 4.0 148 1 0.07 1 0.02 97%
1st T 3,772 5.0 190 1.29 1.03–1.60 1.37 1.06–1.73
2nd–3rd T 5,398 4.3 234 1.1 0.89–1.35 1.26 1.01–1.57
Missing 220 1.4 3
Stavudine
Unexposed 12,127 4.3 520 1 0.17 1 0.43 71%
1st T 819 5.6 46 1.33 0.97–1.81 1.18 0.86–1.63
2nd–3rd T 169 5.3 9 1.26 0.64–2.47 1.34 0.67–2.67
Missing 9 0 0
Abacavir
Unexposed 11,985 4.4 526 1 0.69 1 0.78 76%
1st T 920 4.7 43 1.07 0.78–1.47 1.01 0.73–1.41
2nd–3rd T 184 3.3 6 0.73 0.32–1.66 0.74 0.32–1.71
Missing 35 0 0
Tenofovir
Unexposed 12,043 4.5 536 1 0.51 1 0.3 72%
1st T 823 3.6 30 0.81 0.56–1.18 0.75 0.51–1.10
2nd–3rd T 208 3.8 8 0.86 0.42–1.75 0.82 0.40–1.69
Missing 50 2.0 1
Emtricitabine
Unexposed 12,420 4.5 553 1 0.07 1 0.04 55%
1st T 552 2.5 14 0.56 0.33–0.96 0.52 0.30–0.90
2nd–3rd T 118 5.9 7 1.35 0.63–2.92 1.38 0.63–3.02
Missing 34 2.9 1
Any NRTI
Unexposed 176 2.3 4 1 0.04 1 0.09 14%
1st T 5,288 4.9 261 2.23 0.82–6.06 2.36 0.86–6.47
2nd–3rd T 7,375 4.2 307 1.87 0.69–5.07 2.04 0.75–5.59
Missing 285 1.1 3
Nevirapine
Unexposed 11,936 4.4 521 1 0.94 1 0.82 71%
1st T 819 4.5 37 1.03 0.74–1.46 1 0.71–1.42
2nd–3rd T 342 4.7 16 1.07 0.64–1.79 1.18 0.70–2.00
Missing 27 3.7 1
Efavirenz
Unexposed 12,729 4.4 554 1 0.42 1 0.7 41%
1st T 372 5.4 20 1.25 0.79–1.98 1.16 0.73–1.85
2nd–3rd T 17 5.9 1 1.37 0.18–10.4 1.83 0.23–14.5
Missing 6 0 0
Any NNRTI
Unexposed 11,587 4.3 504 1 0.86 1 0.78 84%
1st T 1161 4.7 54 1.07 0.80–1.43 1.02 0.76–1.37
2nd–3rd T 343 4.7 16 1.08 0.65–1.79 1.21 0.72–2.03
Missing 33 3.0 1
Amprenavir
Unexposed 13,069 4.4 573 1 0.56 1 0.96 6%
1st T 23 0 0 NA NA
2nd–3rd T 32 6.3 2 1.45 0.35–6.10 0.96 0.22–4.14
Ritonavir
Unexposed 7,808 4.6 362 1 0.39 1 0.45 97%
1st T 2,196 4.1 91 0.89 0.70–1.12 0.86 0.67–1.10
2nd–3rd T 2,891 4.1 119 0.88 0.71–1.09 0.92 0.74–1.15
Missing 229 1.3 3
Saquinavir
Unexposed 12,403 4.4 542 1 0.21 1 0.31 35%
1st T 308 6.2 19 1.44 0.89–2.31 1.4 0.86–2.27
2nd–3rd T 400 3.5 14 0.79 0.46–1.36 0.84 0.48–1.46
Missing 13 0 0
Nelfinavir
Unexposed 11,070 4.4 482 1 0.87 1 0.82 60%
1st T 625 4.3 27 0.99 0.67–1.47 0.89 0.59–1.33
2nd–3rd T 1,419 4.7 66 1.07 0.82–1.39 1.03 0.78–1.36
Missing 10 0 0
Indinavir
Unexposed 12,492 4.3 540 1 0.01 0.03 38%
1st T 350 7.7 27 1.85 1.24–2.77 1.66 1.09–2.53
2nd–3rd T 275 2.9 8 0.66 0.33–1.35 0.69 0.33–1.44
Missing 7 0 0
Atazanavir
Unexposed 12,591 4.4 560 1 0.19 0.18 47%
1st T 447 2.7 12 0.59 0.33–1.06 0.58 0.32–1.05
2nd–3rd T 66 4.5 3 1.02 0.32–3.27 1.23 0.38–4.01
Missing 20 0 0
Lopinavir
Unexposed 9,225 4.4 406 1 0.67 1 0.42 88%
1st T 1,333 4.1 55 0.93 0.70–1.25 0.92 0.68–1.23
2nd–3rd T 2,371 4.7 112 1.08 0.87–1.33 1.13 0.90–1.41
Missing 195 1.0 2
Fosamprenavir
Unexposed 12,873 4.4 564 1 0.73 0.77 22%
1st T 172 5.2 9 1.21 0.61–2.37 1.13 0.57–2.25
2nd–3rd T 72 2.8 2 0.62 0.15–2.55 0.63 0.15–2.61
Missing 7 0.0 0
Any PI
Unexposed 5,642 4.6 257 1 0.81 0.69 99%
1st T 3,125 4.4 139 0.98 0.79–1.20 0.91 0.73–1.13
2nd–3rd T 4,110 4.3 176 0.94 0.77–1.14 0.94 0.77–1.16
Missing 247 1.2 3

Missing data were excluded from all statistical tests.

aTotal number of patients exposed in each category.

bNumber of birth defects observed among N patients of the category.

cORs obtained by univariate logistic regression.

dGlobal p-value for exposure to each drug, including the three categories (no exposure, exposure in the first trimester, and exposure in the 2nd or 3rd trimester).

eAOR obtained by multivariate logistic regression, adjusted systematically for mother's age, geographical origin, IDU, and maternity center.

fPower for an OR of 1.5 concerning exposure in the first trimester to each drug as compared to no exposure to this drug.

BD, birth defect; NA, not applicable/no child in this category; T, trimester.


[TableWrap ID: pmed-1001635-t003] doi: 10.1371/journal.pmed.1001635.t003.
Table 3  Evolution of antiretroviral drugs during the study period.
ART Time Period p-Value
1994–1996 1997–1999 2000–2004 2005–2010
Any ART (n) 1,055 1,884 4,555 5,342
1st T (percent) 19.1 35.7 38.5 51.7 <0.001
2nd–3rd T (percent) 80.9 64.3 61.5 48.3
Monotherapy ZDV (n) 1,002 376 817 63
1st T (percent) 17.0 8.0 3.3 7.9 <0.001
2nd–3rd T (percent) 83.0 92.0 96.7 92.1
Dual-therapy NRTI (n) 18 581 721 120
1st T (percent) 50.0 38.0 24.8 13.3 <0.001
2nd–3rd T (percent) 50.0 62.0 75.2 86.7
Combination ART (n) 3 307 2,745 5,084
1st T (percent) 100.0 79.8 51.9 53.0 <0.001
2nd–3rd T (percent) 0 20.2 48.1 47.0
ZDV (n) 1,055 1,885 4,559 5,413
No ZDV (percent) 0 8.7 13.6 25.3 <0.001
1st T (percent) 18.4 22.9 23.4 29.1
2nd–3rd T (percent) 81.6 68.4 63.0 45.6
EFV (n) 1,080 1,889 4,567 5,582
No EFV (percent) 100 99.6 96.3 96.2 <0.001
1st T (percent) 0 0.3 3.4 3.7
2nd–3rd T (percent) 0 0.1 0.2 0.1

EFV, efavirenz; T, trimester; ZDV, zidovudine.


[TableWrap ID: pmed-1001635-t004] doi: 10.1371/journal.pmed.1001635.t004.
Table 4  Maternal and neonatal characteristics, and associations with overall birth defects, according to the EUROCAT classification (French Perinatal Cohort [ANRS CO1/CO11]).
Characteristic Na Percent with BD Number with BDb OR 95% CI p-Valuec
Maternal age (years)
<25 1,502 3.4 51 1 0.046
25–34 7,800 4.3 337 1.28 0.95–1.73
>35 3,781 4.9 186 1.47 1.07–2.02
Missing 41 2.4 1
Geographical origin
France 2,818 4.7 132 1 0.31
Sub-Saharan Africa 7,920 4.2 331 0.89 0.72–1.09
Other 2,225 4.8 107 1.03 0.79–1.33
Missing 161 3.1 5
IDU during pregnancy
No 12,622 4.4 557 1 0.69
Yes 264 4.9 13 1.12 0.64–1.97
Missing 238 2.1 5
CD4 count (cells/mm3)
>350 7,605 4.6 353 1 0.56
200–350 2,361 4.4 103 0.93 0.75–1.17
<200 1,059 5.2 55 1.12 0.84–1.51
Missing 2,099 3.0 64
Viral load (copies/ml)
<400 8,710 4.5 391 1 0.76
400–1,000 668 5.4 36 1.21 0.85–1.72
1,000–10,000 1,292 4.6 60 1.04 0.78–1.36
>10,000 649 4.6 30 1.03 0.71–1.51
Missing 1,805 3.2 58
Parity
Nulliparous 4,909 4.3 209 1 0.52
Parous 8,137 4.5 366 1.06 0.89–1.26
Missing 78 0.0 0
Pregnancy
Singleton 12,545 4.4 547 1 0.59
Multiple 579 4.8 28 1.12 0.76–1.65
Gender of neonate
Male 6,567 4.9 322 1 0.01
Female 6,265 4.0 249 0.8 0.68–0.95
Missing 292 1.4 4
Neonate HIV-infected
Yes 174 2.9 5 0.62 0.25–1.52 0.29
No 11,777 4.5 535 1
Undetermined 1,173 3.0 35
Year of birth
1994–1996 1,080 3.1 34 0.8 0.56–1.16 0.001
1997–1999 1,889 5.7 107 1.49 1.17–1.88
2000–2004 4,567 4.8 217 1.23 1.02–1.50
2005–2010 5,588 3.9 217 1
Mode of deliveryd
Vaginal 5,076 3.9 197 1 0.002
Cesarean 2,388 5.1 352 1.33 1.11–1.59
Missing 1,144 2.3 26
Premature delivery (<37 wk)a
Yes 1,901 6.6 126 1.69 1.38–2.07 <0.001
No 11,154 4.0 449 1
Missing 69 0.0 0
Low birth weight (<2,500 g)d
Yes 2,127 6.9 146 1.78 1.47–2.16 <0.001
No 10,713 4.0 426 1
Missing 284 1.1 3

aTotal patients in each category.

bNumber of birth defects among the N patients of the category.

cχ2 test or Fisher's exact test; missing data excluded.

dAssociation with mode of delivery, premature delivery and low birth weight could be a consequence but not a risk factor for birth defects, and thus were not included in the multivariate analysis.


[TableWrap ID: pmed-1001635-t005] doi: 10.1371/journal.pmed.1001635.t005.
Table 5  Association between overall birth defects and antiretroviral drugs according to MACDP classification (French Perinatal Cohort [ANRS CO1/CO11]).
In Utero Exposure Na Percent with BD Number with BDb ORc 95% CI p-Valued AORe 95% CI p-Valued
Zidovudine
Unexposed 2,152 6.4 137 1 0.007 1 0.002
1st T 3,267 8.3 271 1.32 1.07–1.63 1.41 1.13–1.76
2nd–3rd T 7,493 6.7 502 1.05 0.87–1.28 1.1 0.89–1.35
Didanosine
Unexposed 11,651 6.8 796 1 0.002 1 0.006
1st T 927 9.7 90 1.46 1.16–1.84 1.4 1.11–1.78
2nd–3rd T 529 5.3 28 0.76 0.51–1.12 0.77 0.52–1.14
Zalcitabine
Unexposed 13,010 6.9 900 1 0.02 1 0.01
1st T 103 13.6 14 2.11 1.20–3.72 2.16 1.17–4.00
2nd–3rd T 11 0 0 NA NA
Lamivudine
Unexposed 3,734 6.3 237 1 0.006 1 <0.001
1st T 3,772 8.2 308 1.31 1.10–1.56 1.43 1.18–1.72
2nd–3rd T 5,398 6.7 362 1.06 0.90–1.26 1.2 1.01–1.44
Stavudine
Unexposed 12,127 6.9 838 1 0.48 1 0.75
1st T 819 7.9 65 1.16 0.89–1.50 1.07 0.82–1.41
2nd–3rd T 169 5.9 10 0.84 0.44–1.60 0.84 0.43–1.61
Abacavir
Unexposed 11,985 7 833 1 0.48 1 0.51
1st T 920 7.7 71 1.12 0.87–1.44 1.09 0.84–1.42
2nd–3rd T 184 5.4 10 0.77 0.40–1.46 0.73 0.38–1.41
Tenofovir
Unexposed 12,043 7.1 854 1 0.05 1 0.03
1st T 823 6.2 51 0.89 0.66–1.18 0.8 0.59–1.08
2nd–3rd T 208 3.4 7 0.46 0.21–0.97 0.42 0.19–0.90
Emtricitabine
Unexposed 12,420 7.1 877 1 0.22 1 0.13
1st T 552 5.6 31 0.81 0.56–1.16 0.74 0.51–1.07
2nd–3rd T 118 4.2 5 0.58 0.24–1.43 0.55 0.22–1.36
Any NRTI
Unexposed 176 4 7 1 <0.001 1 0.002
1st T 5,288 8 425 2.12 0.99–4.53 2.13 0.98–4.61
2nd–3rd T 7,375 6.5 476 1.68 0.78–3.58 1.69 0.78–3.65
Nevirapine
Unexposed 11,936 6.9 821 1 0.1 1 0.11
1st T 819 8.7 71 1.28 0.99–1.65 1.31 1.00–1.69
2nd–3rd T 342 5.6 19 0.79 0.50–1.27 0.88 0.54–1.41
Efavirenz
Unexposed 12,729 6.9 878 1 0.21 1 0.31
1st T 372 9.4 35 1.4 0.98–1.99 1.32 0.92–1.91
2nd–3rd T 17 5.9 1 0.84 0.11–6.34 1.06 0.13–8.31
Any NNRTI
Unexposed 11,587 6.8 789 1 0.02 1 0.03
1st T 1,161 8.9 103 1.33 1.07–1.64 1.33 1.07–1.66
2nd–3rd T 343 5.5 19 0.8 0.50–1.28 0.89 0.55–1.44
Amprenavir
Unexposed 13,069 7 909 1 0.45 1 0.3
1st T 23 0 0 NA NA
2nd–3rd T 32 15.6 5 2.47 0.95–6.43 1.68 0.63–4.50
Ritonavir
Unexposed 7,808 7.4 576 1 0.25 1 0.16
1st T 2,196 7 153 0.95 0.79–1.14 0.91 0.75–1.11
2nd–3rd T 2,891 6.2 179 0.83 0.70–0.99 0.84 0.70–1.01
Saquinavir
Unexposed 12,403 7 863 1 0.46 1 0.58
1st T 308 8.4 26 1.23 0.82–1.84 1.21 0.80–1.84
2nd–3rd T 400 6 24 0.85 0.56–1.29 0.9 0.59–1.39
Nelfinavir
Unexposed 11,070 6.8 757 1 0.29 1 0.58
1st T 625 8.5 53 1.26 0.94–1.68 1.17 0.87–1.58
2nd–3rd T 1419 7.3 103 1.06 0.86–1.31 1.02 0.82–1.29
Indinavir
Unexposed 12,492 6.9 859 1 0.006 1 0.04
1st T 350 11.4 40 1.74 1.24–2.44 1.52 1.07–2.17
2nd–3rd T 275 5.5 15 0.78 0.46–1.32 0.76 0.44–1.31
Atazanavir
Unexposed 12,591 7 883 1 0.58 1 0.57
1st T 447 6.3 28 0.88 0.60–1.30 0.85 0.57–1.26
2nd–3rd T 66 4.5 3 0.63 0.20–2.01 0.65 0.20–2.11
Lopinavir
Unexposed 9,225 7.3 669 1 0.36 1 0.4
1st T 1,333 6.4 85 0.88 0.70–1.11 0.86 0.67–1.09
2nd–3rd T 2,371 6.6 156 0.91 0.76–1.08 0.93 0.77–1.12
Fosamprenavir
Unexposed 12,873 7 896 1 0.41 1 0.61
1st T 172 8.7 15 1.27 0.75–2.17 1.18 0.68–2.03
2nd–3rd T 72 4.2 3 0.58 0.18–1.84 0.62 0.19–2.00
Any PI
Unexposed 5,642 7.1 403 1 0.19 1 0.45
1st T 3,125 7.6 237 1.07 0.90–1.26 1.01 0.85–1.21
2nd–3rd T 4,110 6.5 267 0.9 0.77–1.06 0.91 0.77–1.08

Missing data were excluded from all statistical tests.

aTotal of patients exposed in each category.

bNumber of birth defects observed among N patients of the category.

cOR obtained by univariate logistic regression.

dFor exposure to each drug, including the three categories (no exposure, exposure in the first trimester and in the second or third trimester).

eAOR obtained by multivariate logistic regression.

BD, birth defect; NA, not applicable/no child in this category; T, trimester.


[TableWrap ID: pmed-1001635-t006] doi: 10.1371/journal.pmed.1001635.t006.
Table 6  Association between birth defects by organ system and ARV drug exposures (French Perinatal Cohort [ANRS CO1/CO11]).
Type of BD In Utero Exposure Percent with BD n/Na EUROCAT MACDP
LBs Only LBs, TOPs, and SBs LBs Only LBs, TOPs, and SBs
OR 95% CI p-Value AOR 95% CI p-Value AOR 95% CI p-Value AOR 95% CI p-Value AOR 95% CI p-Value
Central nervous system EFV 0.13 0.16 0.22 0.04
Unexposed 0.4 56/12,729 1 1 1 1 1 0.07
1st T 1.1 4/372 2.5 0.9–6.8 2.1 0.7–5.9 1.9 0.7–5.4 3.0 1.1–8.5 2.7 0.9–7.5
2nd–3rd T 0.0 0/17 NA NA NA NA NA
EFV, 1st T 0.31 0.30 0.41
No drugs, 1st T 0.4 32/7,448 1 1 1 1 0.08 1 0.14
EFV, 1st T 1.1 4/372 2.5 0.9–7.2 1.8 0.6–5.4 1.7 0.6–5.1 2.5 0.8–7.5 2.3 0.8–6.8
Other, 1st T 0.5 23/5,012 1.1 0.6–1.8 0.8 0.4–1.4 0.8 0.5–1.5 0.7 0.4–1.4 0.8 0.4–1.4
Heart and circulatory system ZDV <0.001 0.003 0.005 0.002 0.004
Unexposed 1.1 23/2,152 1 1 1 1 1
1st T 2.3 74/3,267 2.1 1.3–3.4 2.2 1.3–3.7 2.1 1.3–3.5 2.4 1.4–4.1 2.3 1.4–3.9
2nd–3rd T 1.1 84/7,493 1.1 0.7–1.7 1.1 0.6–1.9 1.1 0.6–1.9 1.4 0.8–2.4 1.4 0.8–2.4
ZDV, 1st T <0.001 0.003 0.006 0.003 0.006
No drugs, 1st T 1.1 83/7,448 1 1 1 1 1
ZDV, 1st T 2.3 74/3,267 2.1 1.5–2.8 2.1 1.3–3.6 2.0 1.2–3.4 1.9 1.2–3.2 1.8 1.1–3.0
Other, 1st T 1.1 24/2,117 1.0 0.6–1.6 1.1 0.6–1.9 1.1 0.6–1.9 0.9 0.5–1.6 0.9 0.5–1.6
Head and neck defects DDI 0.06 0.07 0.07 0.049 0.05
Unexposed 0.2 18/11,651 1 1 1 1 1
1st T 0.5 5/927 3.5 1.3–9.5 3.4 1.1–10.4 3.3 1.1–10.3 1.9 1.1–3.3 1.9 1.1–3.3
2nd–3rd T 0.4 2/529 2.5 0.6–10 2.7 0.6–12.0 2.7 0.6–12.1 0.6 0.2–1.9 0.6 0.2–1.9
DDI, 1st T 0.12 0.12 0.13 0.20 0.20
No drugs, 1st T 0.2 12/7448 1 1 1 1 1
DDI, 1st T 0.5 5/927 3.4 1.2–9.6 2.9 0.8–10.9 2.8 0.7–10.7 1.5 0.8–2.9 1.5 0.8–2.9
Other, 1st T 0.2 8/4,457 1.1 0.5–2.7 NA NA NA NA
IND 0.01 0.04 0.04 0.47 0.49
Unexposed 0.2 22/12,470 1 1 1 1 1
1st T 0.9 3/350 4.9 1.5–16 3.8 1.1–13.8 3.8 1.0–13.7 1.6 0.7–3.5 1.6 0.7–3.5
2nd–3rd T 0 0/275 NA NA NA 0.8 0.2–3.1 0.8 0.2–3.1
IND, 1st T 0.02 0.04 0.04 0.38 0.34
No drugs, 1st T 0.2 12/7,448 1 1 1 1 1
IND, 1st T 0.9 3/350 5.4 1.5–19 4.0 1.1–15.0 4.0 1.1–14.9 1.5 0.6–3.2 1.5 0.7–3.3
Other, 1st T 0.2 10/5,038 1.2 0.5–2.9 NA NA NA NA

All organ system defects significantly associated with ART in multivariate main analysis with either EUROCAT or MACDP classification are presented in this table. AORs obtained by multivariate logistic regression adjusted systematically for maternal age, geographical origin, IDU, and type of maternity center (ranged from 1 to 3 according to the presence of a pediatrician on site, a neonatology unit, or a neonatal intensive care unit), and for all other drugs associated in univariate analysis with p<0.10 to the organ system considered in either classification (central nervous system defects adjusted for didanosine; heart defects adjusted for indinavir, emtricitabine, lamivudine, and zalcitabine; head and neck defects adjusted for zidovudine, zalcitabine, lamivudine, emtricitabine and efavirenz). Univariate analysis showing the association between birth defects by organ system and all drugs evaluated is presented in Table 3. p-Values are global p-value for the three categories in each type of exposure.

aNumber of birth defects/total in exposure category.

BD, birth defect; DDI, didanosine; EFV, efavirenz; IND, indinavir; LB, live birth; NA, not applicable/no child in this category; SB, stillbirth; T, trimester; ZDV, zidovudine.


[TableWrap ID: pmed-1001635-t007] doi: 10.1371/journal.pmed.1001635.t007.
Table 7  Univariate analysis: association between birth defects by organ system and antiretroviral drugs.
In Utero Exposure Central Nervous System Heart and Circulatory System Renal and Urinary System Limb and Musculoskeletal System Head and Neck (Including Eyes and Ears)
EUROCAT (n = 60) MACDP (n = 50) EUROCAT (n = 182) MACDP (n = 198) EUROCAT (n = 53) MACDP (n = 57) EUROCAT (n = 133) MACDP (n = 373) EUROCAT (n = 25) MACDP (n = 129)
OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value OR 95% CI p-Value
Zidovudine
Unexposed 1 0.96 1 0.47 1 <0.001 1 <0.001 1 0.64 1 0.52 1 0.45 1 0.13 1 0.91 1 0.07
1st T 1.1 0.48–2.51 0.66 0.26–1.66 2.14 1.34–3.44 2.45 1.51–3.98 1.13 0.44–2.87 1.22 0.49–3.07 1.32 0.77–2.27 1.29 0.93–1.79 0.79 0.24–2.59 1.39 0.82–2.33
2nd–3rd T 1.11 0.54–2.33 1.02 0.49–2.14 1.05 0.66–1.67 1.34 0.84–2.16 1.4 0.62–3.16 1.52 0.68–3.42 1.05 0.64–1.72 1.03 0.76–1.39 0.8 0.29–2.23 0.87 0.53–1.43
Didanosine
Unexposed 1 0.09 1 0.77 1 0.82 1 0.81 1 0.57 1 0.87 1 0.06 1 0.07 1 0.06 1 0.03
1st T 2.37 1.16–4.85 1.17 0.42–3.27 1.18 0.69–2.01 1.15 0.69–1.93 1.34 0.53–3.37 1.26 0.50–3.16 1.64 0.95–2.81 1.45 1.02–2.05 3.5 1.30–9.46 1.97 1.18–3.31
2nd–3rd T 1.38 0.43–4.44 1.54 0.48–4.98 0.96 0.45–2.06 0.88 0.41–1.88 0.47 0.06–3.40 0.88 0.21–3.63 0.38 0.09–1.53 0.74 0.40–1.36 2.45 0.57–10.6 0.6 0.19–1.91
Zalcitabine
Unexposed NA NA 1 0.04 1 0.009 1 0.44 1 0.47 1 0.96 1 0.97 NA 1 0.06
1st T NA NA 2.91 1.06–8.00 3.39 1.36–8.42 2.44 0.33–17.9 2.27 0.31–16.5 0.96 0.13–6.90 1.02 0.32–3.25 NA 3.07 0.96–9.80
2nd–3rd T NA NA NA NA NA NA NA NA NA NA
Lamivudine
Unexposed 1 0.85 1 0.84 1 0.02 1 0.1 1 0.31 1 0.3 1 0.27 1 0.02 1 0.27 1 0.004
1st T 0.89 0.46–1.71 0.8 0.39–1.67 1.48 1.02–2.25 1.36 0.95–1.95 1.35 0.62–2.95 1.32 0.62–2.80 1.3 0.84–2.01 1.29 0.99–1.68 2.48 0.78–7.91 2.07 1.29–3.31
2nd–3rd T 0.84 0.46–1.54 0.91 0.47–1.74 0.94 0.64–1.37 0.97 0.68–1.39 1.7 0.84–3.43 1.68 0.85–3.29 0.94 0.61–1.45 0.92 0.71–1.19 1.9 0.61–5.98 1.28 0.79–2.07
Tenofovir
Unexposed 1 0.93 1 0.65 1 0.21 1 0.69 1 0.82 1 0.85 1 0.86 1 0.03 1 0.75 1 0.21
1st T 1.04 0.38–2.89 1.27 0.48–3.55 0.79 0.40–1.54 0.8 0.42–1.51 0.88 0.27–2.82 1.1 0.40–3.06 0.94 0.46–1.92 0.87 0.56–1.36 1.27 0.30–5.41 0.59 0.24–1.44
2nd–3rd T NA NA 2.11 0.92–4.83 1.27 0.47–3.46 NA NA NA 0.16 0.02–1.15 NA NA
Emtricitabine
Unexposed 1 0.78 1 0.56 1 0.02 1 0.16 1 0.86 1 0.72 1 0.21 1 0.62 NA 1 0.08
1st T 1.18 0.37–3.80 1.44 0.44–4.64 0.65 0.27–1.60 0.59 0.24–1.44 0.88 0.21–3.63 1.25 0.39–4.01 0.52 0.16–1.63 0.87 0.51–1.50 NA 0.35 0.09–1.43
2nd–3rd T NA NA 3.84 1.67–8.85 2.27 0.83–6.22 NA NA NA NA NA NA
Nevirapine
Unexposed 1 0.12 1 0.37 1 0.16 1 0.46 1 0.12 1 0.09 1 0.32 1 0.03 NA 1 0.19
1st T 1.75 0.75–4.10 1.36 0.49–3.79 0.8 0.41–1.57 0.9 0.49–1.66 0.28 0.04–2.02 0.26 0.04–1.88 1.49 0.82–2.71 1.57 1.10–2.23 NA 1.39 0.74–2.58
2nd–3rd T 2.81 1.01–7.83 2.45 0.76–7.93 1.94 0.98–3.83 1.58 0.77–3.24 NA NA 0.15 0.15–2.39 0.63 0.28–1.42 NA 0.3 0.04–2.15
Efavirenz
Unexposed 1 0.13 1 0.04 1 0.46 1 0.51 1 0.66 1 0.77 1 0.67 1 0.11 1 0.2 1 0.04
1st T 2.46 0.89–6.82 3 1.07–8.37 1.18 0.52–2.67 0.89 0.36–2.17 0.66 0.09–4.77 1.25 0.30–5.13 0.79 0.25–2.49 1.56 0.93–2.60 2.99 0.70–12.7 2.29 1.11–4.72
2nd–3rd T NA NA 4.48 0.59–34.0 4.08 0.54–30.9 NA NA NA NA NA NA
Any NNRTI
Unexposed 1 0.03 1 0.1 1 0.19 1 0.47 1 0.13 1 0.28 1 0.44 1 0.01 1 0.84 1 0.05
1st T 2.18 1.10–4.33 2.05 0.96–4.41 0.87 0.51–1.52 0.92 0.55–1.54 0.39 0.09–1.60 0.55 0.17–1.77 1.31 0.76–2.24 1.57 1.15–2.13 0.87 0.20–3.68 1.65 1.00–2.74
2nd–3rd T 2.96 1.06–8.27 2.61 0.80–8.50 1.94 0.98–3.82 1.56 0.77–3.23 NA NA 0.59 0.14–2.38 0.63 0.28–1.43 NA 0.31 0.04–2.21
Nelfinavir
Unexposed 1 0.29 1 0.16 1 0.73 1 0.68 1 0.4 1 0.36 1 0.84 1 0.51 1 0.87 1 0.89
1st T 1.54 0.55–4.30 0.93 0.22–3.87 1.29 0.69–2.39 1.29 0.71–2.32 1.73 0.62–4.85 1.61 0.58–4.51 0.78 0.32–1.90 1.28 0.82–1.99 0.8 0.11–5.98 1.16 0.54–2.50
2nd–3rd T 1.7 0.86–3.38 2.06 1.02–4.14 0.97 0.60–1.58 0.94 0.59–1.50 1.53 0.71–3.26 1.6 0.78–3.28 0.96 0.96–1.67 1.1 0.79–1.51 0.71 0.17–3.02 1.09 0.64–1.88
Indinavir
Unexposed 1 0.59 1 0.22 1 0.07 1 0.04 1 0.04 1 0.06 1 0.86 1 0.64 1 0.03 1 0.21
1st T 1.92 0.60–6.16 2.29 0.71–7.39 2.13 1.11–4.07 2.16 1.16–4.00 3.92 1.55–9.93 3.61 1.43–9.10 1.13 0.41–3.06 1.21 0.68–2.18 4.9 1.46–16.4 2.1 0.97–4.54
2nd–3rd T 0.81 0.11–5.87 NA 0.53 0.13–2.15 0.49 0.12–1.97 1.98 0.48–8.21 1.82 0.44–7.53 0.71 0.18–2.90 0.76 0.34–1.72 NA 0.76 0.19–3.07

NA, not applicable/no child in this category; T, trimester.


[TableWrap ID: pmed-1001635-t008] doi: 10.1371/journal.pmed.1001635.t008.
Table 8  Description of births defects among 13,124 live births (French Perinatal Cohort [ANRS CO1/CO11]).
Organ System Classification (EUROCAT) N
Nervous system 60
Spina bifida 3
Hydrocephalus, dilatation of ventricular system 31
Microcephaly 13
Agenesis/malformation of corpus callosum 4
Pachygyria 1
Cerebral cyst, single or multiple 7
Malformation of spinal cord 1
Eye, ear, face, and neck 25
Anopthalmos 1
Congenital cataract 1
Congenital glaucoma/buphthalmos 5
Congenital ptosis/malformation of eyelid 8
Malformation of lacrymal duct/apparatus 2
Coloboma of iris 1
Aniridia 1
Congenital corneal opacity/malformation of cornea 4
Absence of auditory canal 1
Cyst of tongue 1
CHDs 182
Ventricular septal defects 101
Atrial septal defects 30
Atrioventricular septal defects 1
Tetralogy of Fallot 1
Pulmonary valve stenosis/dysplasia 14
Hypoplastic left heart 1
Coarctation of aorta 6
Tricuspid valve malformation 3
Aortic valve stenosis/malformation 1
Mitral insufficiency 1
Other CHD 2
Patent ductus arteriosus as only CHD in term infants (≥37 wk) 15
Pulmonary artery stenosis/other malformation 6
Respiratory 6
Choanal atresia 3
Underdevelopment of nose 1
Congenital cystic lung 1
Hypoplasia of lung 1
Oro-facial clefts 9
Other malformations 25
Genetic syndromes and microdeletions 7
Chromosomal 24
Teratogenic syndromes with malformations 11
Fetal alcohol syndrome 6
Cytomegalovirus infection resulting in malformation 5
Digestive 21
Esophageal atresia 2
Duodenal atresia 1
Imperforate anus 3
Hirschsprung disease 4
Diaphragmatic hernia 3
Fistula of rectum and anus 2
Microcolon 3
Other malformation of intestines 1
Malformation of bile ducts 1
Duplication of digestive organs 1
Abdominal wall defects 2
Gastroschisis 1
Omphalocele 1
Urinary 53
Renal dysplasia 7
Hydronephrosis/renal pelvis dilatation 25
Renal agenesis, unilateral 5
Renal cyst 2
Pelviureteric junction syndrome 3
Vesicoureteric junction syndrome 2
Megaloureter 3
Duplication of ureter 1
Ectopic kidney 1
Other malformation of kidney or urethra 4
Genital 45
Hypospadias 26
Indeterminate sex 1
Ovarian cyst 10
Malformation of clitoris 4
Agenesis of testis, unilateral 1
Micropenis 3
Limb and musculoskeletal 133
Talipes equinovarus 14
Hip dislocation and/or dysplasia 25
Polydactyly 61
Syndactyly 2
Reduction defect of upper limb 2
Reduction defect of lower limb 4
Other malformation of upper limb 6
Other malformation of lower limb 2
Arthrogryposis multiplex congenita 1
Achondroplasia, hypochondroplasia 1
Amniotic band syndrome 1
Other malformation of skull and bones 14

Total number of defects exceeds 575 because some children were included in several organ systems. Each child was included only once in each organ system.


[TableWrap ID: pmed-1001635-t009] doi: 10.1371/journal.pmed.1001635.t009.
Table 9  Description of birth defects among terminations of pregnancy (French Perinatal Cohort [ANRS CO1/CO11]).
Organ System Classification (EUROCAT) N
Nervous system 5
Anencephaly 1
Spina bifida 1
Agenesis of corpus callosum 1
Anomalies of gyration 1
CHDs 4
Severe heart defects 3
Atrioventricular septal defects 1
Urinary 1
Renal hypoplasia, bilateral 1
Other malformations 5
Multiple congenital malformations 4
Cystic hygroma 1
Genetic and microdeletion syndromes 1
Goldenhar syndrome 1
Chromosomal 9
Trisomy 21 6
Trisomy 13 2
Unbalanced translocation 1


Article Categories:
  • Research Article
Article Categories:
  • Medicine and Health Sciences
    • Infectious Diseases
    • Women's Health
      • Obstetrics and Gynecology


Previous Document:  Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective p...
Next Document:  Spatio-temporal distribution of the timing of start and end of growing season along vertical and hor...